Applied Therapeutics (APLT)
(Delayed Data from NSDQ)
$4.19 USD
-0.06 (-1.41%)
Updated May 17, 2024 04:00 PM ET
After-Market: $4.18 -0.01 (-0.24%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APLT 4.19 -0.06(-1.41%)
Will APLT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for APLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLT
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
APLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
Other News for APLT
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Analysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Insulet (PODD)
Applied Therapeutics Inc (APLT) Reports Q1 2024 Earnings: A Deep Dive into Financials and ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
APLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024